Patient Characteristics (n = 14)
| Characteristic | n |
| Age (y) | |
| Median | 67 |
| Range | 57–82 |
| International Federation of Gynecology and Obstetrics stage | |
| IIIC | 11 |
| IV | 2 |
| Recurrent | 1 |
| Therapy before 18F-FES PET | |
| None | 5 |
| Neoadjuvant chemotherapy | 9 |
| Histologic subtype | |
| High-grade serous | 13 |
| Transitional cell | 1 |
| Serum tumor marker Ca-125 (kU/L) | |
| Median | 138 |
| Range | 18–1,771 |
| Serum estradiol (nmol/L) | |
| Median | 0.04 |
| Range | 0.02–0.06 |
| Serum sex hormone–binding globulin (nmol/L) | |
| Median | 67 |
| Range | 37–142 |